{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:16:15Z","timestamp":1793301375074,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinthera.2024.08.015","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T10:27:26Z","timestamp":1725704846000},"page":"768-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Tolerability of Anti\u2013microRNA-328 Ophthalmic Solution, SHJ002, in Pediatric Subjects: First-in-Human Clinical Study"],"prefix":"10.1016","volume":"46","author":[{"given":"Jiunn-Liang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuy-Tay","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-740X","authenticated-orcid":false,"given":"Suh-Hang H.","family":"Juo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ling","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.015_bib0001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/eye.2013.256","article-title":"Myopia, an underrated global challenge to vision: where the current data takes us on myopia control","volume":"28","author":"Holden","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/OPX.0b013e3181a6a225","article-title":"Treatment options for myopia","volume":"86","author":"Gwiazda","year":"2009","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0003","unstructured":"World Health Organization. The impact of myopia and high myopia. Report of the Joint World Health Organization\u2013Brien Holden Vision Institute Global Scientific Meeting on Myopia. https:\/\/www.who.int\/blindness\/causes\/MyopiaReportforWeb.pdf. Accessed October 12, 2020."},{"key":"10.1016\/j.clinthera.2024.08.015_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0006","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/aos.15761","article-title":"Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population","volume":"102","author":"Loughman","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0007","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1167\/iovs.10-5859","article-title":"A functional polymorphism at 3\u2032UTR of the PAX6 gene may confer risk for extreme myopia in the Chinese","volume":"52","author":"Liang","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0008","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1167\/iovs.11-9272","article-title":"MicroRNA-328 may influence myopia development by mediating the PAX6 gene","volume":"53","author":"Chen","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/iovs.63.12.11","article-title":"miR-328-3p affects axial length via multiple routes and anti-miR-328-3p possesses a potential to control myopia progression","volume":"63","author":"Liang","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/1389557515666150324123208","article-title":"MicroRNA therapeutics: the next magic bullet?","volume":"15","author":"Simonson","year":"2015","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","article-title":"Progress in corneal wound healing","volume":"49","author":"Ljubimov","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2024.109905","article-title":"Targeting microRNA in myopia: current insights","volume":"243","author":"Zhuang","year":"2024","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0013","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/iovs.64.5.22","article-title":"Exogenous all-trans retinoic acid induces myopia and alters scleral biomechanics in mice","volume":"64","author":"Brown","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.visres.2003.11.002","article-title":"Retinoic acid signals the direction of ocular elongation in the guinea pig eye","volume":"44","author":"McFadden","year":"2004","journal-title":"Vision Res"},{"key":"10.1016\/j.clinthera.2024.08.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.10.001","article-title":"Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century","volume":"17","author":"Watson","year":"2019","journal-title":"EClinicalMedicine"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T02:43:47Z","timestamp":1730342627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0149291824002388"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Anti\u2013microRNA-328 Ophthalmic Solution, SHJ002, in Pediatric Subjects: First-in-Human Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}